FDA again extends review of Pfizer's Prevnar 13

12/30/2009 | Wall Street Journal, The · Yahoo!

Pfizer announced that the FDA has not completed its review of Prevnar 13, a new version of its vaccine for pneumococcal disease in children. The agency had also rescheduled its approval decision on the product in August. A company official said Pfizer remains confident in its application for Prevnar 13 despite the delays.

View Full Article in:

Wall Street Journal, The · Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC